Resistent arterial hypertension


Cite item

Full Text

Full Text

Резистентная артериальная гипертония. -
×

About the authors

I E Chazova

V V Fomin

References

  1. Рекомендации ВНОК по профилактике, диагностике и лечению артериальной гипертонии (проект второго пересмотра). Кардиовас. тер. и профилакт. 2004; 3: 105-120.
  2. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J. Hypertens. 2007; 25: 1105-1187.
  3. Chobanian A. V., Bakris G. L., Black H. R. et al. The Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC VI report. J. A. M. A. 2003; 289: 2560-2571.
  4. Wolf-Maier K., Cooper R. S., Kramer H. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43:10-17.
  5. Macedo M. E., Lima M. J., Silva A. O. et al. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J. Hypertens. 2005; 23: 1661-1666.
  6. Шальнова С. А. Проблемы лечения артериальной гипертонии. Кардиоваск. тер. и профилакт. 2003; 3: 17-21.
  7. Garg J. Р., Elliott W. J., Folker A. et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am. J. Hypertens. 2005; 18 (5, pt 1): 619-626.
  8. Brown M. A., Buddie M. L., Martin A. Is resistant hypertension really resistant? Am. J. Hypertens. 2001; 14 (12): 1263-1269.
  9. Чазова И. Е., Мычка В. Б. Метаболический синдром. М.; 2004.
  10. Martell N., Rodriguez-Cerrillo М., Grobbee D. E. et al. High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension. Blood Press. 2003; 12 (3): 149-154.
  11. Чазова И. E., Литвин А. Ю. (ред.) Артериальная гипертония и синдром обструктивного апноэ во время сна. В кн.: Чазов Е. И., Чазова И. Е. (ред.) Руководство по артериальной гипертонии. М.: Media Medica; 2005, 182-200.
  12. Borgel J., Sanner В. M., Keskin F. et al. Obstructive sleep apnoea and blood pressure. Am. J. Hypertens. 2004; 17 (12): 1081-1087
  13. Goodfriend T. L., Calhoun D. A. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43 (3): 518-524.
  14. Fruhbeck G. The adipose tissue as a source of vasoactive factors. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2004; 2: 197-208.
  15. Barton M., Carmona R., Morawietz H. et al. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 2000; 35 (1, pt 2): 329-336.
  16. Barton M., Carmona R., Ortmann J. et al. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int. J. Biochem. Cell Biol. 2003; 35: 826-837.
  17. Сагинова E. А., Федорова E. Ю., Фомин В. В. и др. Формирование поражения почек у больных ожирением. Тер. арх. 2006; 5: 36-41.
  18. Quehenberger P., Exner М., Sunder-Plassmann R. et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ. Res. 2002; 90: 711-718.
  19. Eid H. M., Arnesen H., Hjerkinn E. M. et al. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 2004; 53: 1574-1579.
  20. Mather K. J., Lteif A., Steinberg H. O., Baron A. D. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004; 53: 2060-2066.
  21. Calhoun D. A., Nishizaka M. K., Zaman M. A. et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40 (6): 892-896.
  22. Шхвацабая И. К., Чихладзе Н. М. Гиперальдостеронизм и артериальная гипертония. М.; 1984.
  23. Stewart P. М. Mineralocorticoid hypertension. Lancet 1999; 353: 1341-1347.
  24. Mosso L., Carvajal C., Gonzales A. et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165.
  25. Umpierrez G. E., Cantey P., Smiley D. et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabet. Care 2007; 30 (7): 1699-1703.
  26. Yong W. F. Primary aldosteronism: update on diagnosis and treatment. Endocrinologist 1997; 7: 213-221.
  27. Sartori M., Calò L. A., Mascagna V. et al. Aldosterone and refractory hypertension: a prospective cohort study. Am. J. Hypertens. 2006; 19 (4): 373-379.
  28. Stowasser M., Gordon R. D., Gunasekera T. G. et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J. Hypertens. 2003; 21 (11): 2149-2157.
  29. Vasan R. S., Evans J. C., Larson M. G. et al. Serum aldosterone and the insidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 2004; 351: 33-42.
  30. Duffy S. J., Biegelsen E. S., Eberhardt R. T. et al. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension 2005; 46 (4): 707-713.
  31. Strauch В., Petrak O., Wichterle D. et al. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am. J. Hypertens. 2006; 19 (9): 909-914.
  32. Pang Т. C., Bambach C., Monaghan J. C. et al. Outcomes of laparoscopic adrenalectomy for hyperaldosteronism. Aust. N. Z. J. Surg. 2007; 77 (9): 768-773.
  33. Weinberger M. H., White W. В., Ruilope L. M. et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am. Heart J. 2005; 150 (3): 426-433.
  34. Reisch N., Peczkowska M., Januszewicz A., Neumann H. P. Pheochromocytoma: presentation, diagnosis and treatment. J. Hypertens. 2006; 24 (12): 2331-2339.
  35. Cryer P. E. Phaeochromocytoma. Clin. Endocrinol. Metab. 1985; 14 (1): 203-220.
  36. Maher E. R. Genetics of phaeochromocytoma. Br. Med. Bull. 2006; 79-80: 141-151.
  37. Mannelli M., Ianni L., Cilotti A., Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur. J. Endocrinol. 1999; 141 (6): 619-624.
  38. Václavik J., Stejskal D., Lacnák B. et al. Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J. Hypertens. 2007; 25 (7): 1427-1431.
  39. Lenders J. W., Pacak K., Walther M. M. et al. Biochemical diagnosis of pheochromocytoma: which test is best? J. A. M. A. 2002; 287 (11): 1427-1434.
  40. Slovut D. P., Olin J. W. Fibromuscular dysplasia. N. Engl. J. Med. 2004; 350: 1862-1871.
  41. Broekhuizen-de Gast H. S., Tiel-van Buul M. M., Van Beek E. J. Severe hypertension in children with renovascular disease. Clin. Nucl. Med. 2001; 26 (7): 606-609.
  42. Kaneko K., Someya Т., Ohtaki R. et al. Congenital fibromuscular dysplasia involving multivessels in an infant with fatal outcome. Eur. J. Pediatr. 2004; 163 (4-5): 241-244.
  43. Luscher T. F., Keller H. M., Imhof H. G. et al. Fibromuscular hyperplasia: extension of the disease and therapeutic outcome: results of the University Hospital Zurich Cooperative Study on Fibromuscular Hyperplasia. Nephron 1986; 44: 109-114.
  44. Schievink W. I., Bjornsson J., Parisi J. E, Prakash U. B. Arterial fibromuscular dysplasia associated with severe alpha 1-antitrypsin deficiency. Mayo Clin. Proc. 1994; 69 (11): 1040-1043.
  45. Bofinger A., Hawley C., Fisher P. et al. Polymorphisms of the renin-angiotensin system in patients with multifocal renal arterial fibromuscular dysplasia. J. Hum. Hypertens. 2001; 15 (3): 185-190.
  46. Bofinger A., Hawley C., Fisher P. et al. Increased severity of multifocal renal arterial fibromuscular dysplasia in smokers. J. Hum. Hypertens. 1999; 13 (8): 517-520.
  47. Airoldi F., Palatresi S., Marana I. et al. Angioplasty of atherosclerotic and fibromuscular renal artery stenosis: time course and predicting factors of the effects on renal function. Am. J. Hypertens. 2000; 13 (11): 1210-1217.
  48. Alhadad A., Mattiasson I., Ivancev K. et al. Revascularisation of renal artery stenosis caused by fibromuscular dysplasia: effects on blood pressure during 7-year follow-up are influenced by duration of hypertension and branch artery stenosis. J. Hum. Hypertens. 2005; 19 (10): 761-767.
  49. Beseth B. D., Quinones-Baldrich W. J. Renal artery aneurysm secondary to fibromuscular dysplasia in a young patient. Ann. Vase. Surg. 2005; 19 (5): 605-608.
  50. Мычка В. Б., Акчурин Р. С., Синицын В. Е. и др. Случай своевременной диагностики и оперативного лечения реноваскулярной артериальной гипертонии у больной с фибромускулярной дисплазией почечных артерий и развитием аневризмы. Тер. арх. 2001; 4: 59-61.
  51. Фомин В. В., Моисеев С. В., Швецов М. Ю. и др. Артериальная гипертония при ишемической болезни почек: клинические особенности и течение. Тер. арх. 2005; 6: 27-31.
  52. Weber-Mzell D., Kotanko P., Schumacher M. et al. Coronary anatomy predicts presence or absence of renal artery stenosis. A prospective study in patients undergoing cardiac catheterization for suspected coronary artery disease. Eur. Heart J. 2002; 23: 1684-1691.
  53. Alcazar J. M., Marin R., Gomez-Campedra F. et al. Clinical charasteristics of ischaemic renal disease. Nephrol. Dial. Transplant. 2001; 16 (suppl. 1): 74-77.
  54. Zhang Y., Ge J. В., Qian J. Y., Ye Z. B. Prevalence and risk factors of atherosclerotic renal artery stenosis in 1200 Chinese patients undergoing coronary angiography. Nephron Clin. Pract. 2006; 104 (4): cl85-cl92.
  55. Johansson M., Herlitz H., Jensen G. et al. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. J. Hypertens. 1999; 17: 1743-1750.
  56. Courreges J. P., Bacha J., Aboud E., Pradier P. Prevalence of renal artery stenosis in type 2 diabetes. Diabet. Metab. 2000; 26 (suppl. 4): 90-96.
  57. Фомин В. В., Таронишвили О. И., Швецов М. Ю. и др. Нарастающая азотемия, спровоцированная назначением ингибитора ангиотензинпревращающего фермента при ишемической болезни почек. Тер. арх. 2004; 9: 66-70.
  58. Lederman R. J., Mendelsohn F. О., Santos R. et al. Primary renal artery stenting: characteristics and outcomes after 363 procedures. Am. Heart J. 2001; 142: 314-323.
  59. Ridao N., Luno J., Garsia de Vinuesa S. et al. Prevalence of hypertesion in renal disease. Nephrol. Dial. Transplant. 2001; 16 (suppl. 1): 70-73.
  60. Campese V. М., Mitra N., Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int. 2006; 69 (6): 967-973.
  61. Кутырина И. M., Мартынов С. А., Швецов М. Ю. и др. Артериальная гипертония при хроническом гломерулонефрите: частота выявления и эффективность лечения. Тер. арх. 2004; 9: 10-15.
  62. Gyamlani G., Geraci S. A. Secondary hypertension due to drugs and toxins. South. Med. J. 2007; 100 (7): 692-699.
  63. Мухин H. А. Профилактическая нефрология и образ жизни современного человека. Тер. арх. 1993; 6: 4-7
  64. DeBroe М. Е., Elseviers М. М., Bengtsson U. et al. Analgesic nephropathy. Nephrol. Dial. Transplant. 1996; 11: 2407-2408.
  65. Morgan Т., Anderson A. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J. Clin. Hypertens. (Greenwich) 2003; 5 (1): 53-57.
  66. de Leeuw P. W. Drug-induced hypertension. Recognition and management in older patients. Drugs Aging 1997; 11 (3): 178-185.
  67. Bradlay J. G. Nonprescription drugs and arterial hypertension. Which ones affect blood pressure? Postgrad. Med. 1991; 89 (6): 195-197.
  68. Chua S. S., Benrimoj S. I. Non-prescription sympathomimetic agents and hypertension. Med. Toxicol. Adverse Drug. Exp. 1988; 3 (5): 387-417.
  69. Cantu C., Arauz A., Murillo-Bonilla L. M. et al. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke 2003; 34 (7): 1667-1672.
  70. Тареев E. M. Гипертоническая болезнь. M., 1948.
  71. Арабидзе Г. Г. Злокачественная артериальная гипертония. Кардиология 1985; 1: 5-11.
  72. Muxfeldt Е. S., Bloch К. V., Nogueira A. R. et al. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press. Monit. 2003; 8 (5): 181-185.
  73. Muxfeldt E. S., Bloch К. V., Nogueira Ada R., Salles G. F. True resistant hypertension: is it possible to be recognized in the office? Am. J. Hypertens. 2005; 18 (12. pt 1): 1534-1540.
  74. Salles G. F., Fiszman R., Cardoso С. R., Muxfeldt E. S. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension 2007; 50 (4): 723-728.
  75. Nogueira Ada R., Fernandes A. S., Coutinho E. S. et al. Factors associated with microalbuminuria in resistant hypertension. Int. J. Cardiol. 2007; 121 (1): 86-87.
  76. Pierdomenico S. D., Lapenna D., Bucci A. et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant and true resistant hypertension. Am. J. Hypertens. 2005; 18 (11): 1422-1428.
  77. Pierdomenico S. D., Lapenna D., Di Tommaso R. et al. Cardiovascular risk in patients receiving double therapy with false and true nonresponder hypertension. Blood Press. Monit. 2006; 11 (6): 303-307.
  78. Grajek S., Cieslihski A., Mitkowski P. et al. Results of long-term medical treatment of patients with arterial hypertension complicated by aortic dissection. J. Hum. Hypertens. 1995; 9 (12): 987-992.
  79. Eggebrecht H., Schmermund A., von Birgelen C. et al. Resistant hypertension in patients with chronic aortic dissection. J. Hum. Hypertens. 2005; 19 (3): 227-231.
  80. Freitas S. R., Cabello P. H, Moura-Neto R. S. et al. Analysis of renin-angiotensin-aldosterone system gene polymorphisms in resistant hypertension. Braz. J. Med. Biol. Res. 2007; 40 (3): 309-316.
  81. Veglio F., Rabbia F., Riva P. et al. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin. Exp. Hypertens. 2001; 23 (3): 203-211.
  82. Mezzetti A., Pierdomenico S. D., Costantini F. et al. White-coat resistant hypertension. Am. J. Hypertens. 1997; 10 (11): 1302-1307.
  83. Oikawa Т., Obara Т., Ohkubo T. et al. Characteristics of resistant hypertension determined by self-measured blood pressure at home and office blood pressure measurements: the J-HOME study. J. Hypertens. 2006; 24 (9): 1737-1743.
  84. Werlemann В. C., Offers E., Kolloch R. Compliance problems in therapy-resistant hypertension. Herz 2004; 29 (3): 271-275.
  85. Degli Esposti L., Degli Esposti E., Valpiani G. et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin. Ther. 2002; 24: 1347-1357.
  86. Wetzels G. E., Nelemans P., Schouten J. S., Prins M. H. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J. Hypertens. 2004; 22: 1849-1855.
  87. Patel В. V., Remigio-Baker R. A., Mehta D. et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J. Clin. Hypertens. (Greenwich) 2007; 9 (9): 692-700.
  88. Fodor G. J., Kotrec M., Bacskai K. et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study. J. Hypertens. 2005; 23: 1261-1266.
  89. Чазова И. E., Ратова Л. Г. Комбинированная терапия артериальной гипертонии. Сердце. 2005; 4 (3): 120-126.
  90. Filippone J. D., Bisognano J. D. Baroreflex stimulation in the treatment of hypertension. Curr. Opin. Nephrol. Hypertens. 2007; 16 (5): 403-408.
  91. Illig К. A., Levy M., Sanchez L. et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J. Vase. Surg. 2006; 44 (6): 1213-1218.
  92. Handler J. Maximizing diuretic therapy in resistant hypertension. J. Clin. Hypertens. (Greenwich) 2007; 9 (10): 802-806.
  93. Hermida R. C., Ayala D. E., Calvo C. et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 2005; 46 (4): 1053-1059.
  94. Berecek К. H., Farag A., Bahtiyar G. et al. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr. Hypertens. Rep. 2004; 6 (3): 211-212.
  95. Ouzan J., Pérault C., Lincoff A. M. et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am. J. Hypertens. 2002; 15 (4, pt. 1): 333-339.
  96. Lim P. O., Jung R. Т., MacDonald Т. M. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br. J. Clin. Pharmacol. 1999; 48 (5): 756-760.
  97. Chapman N., Dobson J., Wilson S. et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49 (4): 839-845.
  98. Black H. R., Bakris G. L., Weber M. A. et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J. Clin. Hypertens. (Greenwich) 2007; 9 (10): 760-769.
  99. Gradman A. H., Schmieder R. E., Lins R. L. et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111 (8): 1012-1018.
  100. Villamil A., Chrysant S. G., Calhoun D. et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. 2007; 25 (1): 217-226.
  101. Drummond W., Munger M. A., Rafique Essop M. et al. Antihypertensive efficacy of the oral direct Renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J. Clin. Hypertens. (Greenwich) 2007; 9 (10): 742-750.
  102. O'Brien E., Barton J., Nussberger J. et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49 (2): 276-284.
  103. Oparil S., Yarows S. A., Patel S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 2007; 370: 221-229.
  104. Philipp Т., Smith T. R., Glazer R. et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin. Ther. 2007; 29 (4): 563-580.
  105. Smith T. R, Philipp Т., Vaisse B. et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J. Clin. Hypertens. (Greenwich) 2007; 9 (5): 355-364.
  106. Fogari R., Zoppi A., Derosa G. et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J. Hum. Hypertens. 2007; 21 (3): 220-224.

Copyright (c) 2008 Chazova I.E., Fomin V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies